跳至主要内容
临床试验/NCT01812525
NCT01812525已完成3 期

Moderate to Severe Bronchiolitis: Standard Therapy Versus Therapy With NaCl 3%

Raphaelle Jaquet-Pilloud1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2013年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
120
试验地点
1
主要终点
length of hospital stay

研究概览

简要总结

Our study will investigate inhalation therapy of NaCl 3% compared to standard therapy with no inhalation in the treatment of moderate to severe bronchiolitis. The impact on length of hospital stay will be analyzed.

详细描述

Acute viral bronchiolitis is the most common lower respiratory tract infection in the first year of life and leads to a large number of hospital admissions. The only recommended treatment is supportive. However many different types of drug inhalations have been studied but their efficacy remains controversial.

Our study will compare recommended supportive therapy to supportive therapy combined to hypertonic saline (NaCl 3%) inhalations in the treatment of moderate to severe bronchiolitis. This will be the first study to use a true control group with no inhalation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
6 Weeks 至 24 Months(Child)
性别
All
接受健康志愿者

入选标准

  • children between ages 6 weeks to 24 months
  • first episode of wheezing
  • diagnosis of moderate to severe bronchiolitis: The patients are ranked as moderately to severely ill according to the Wang clinical severity score

排除标准

  • Children with mild bronchiolitis (Wang score < 5)
  • Children with pre-existent cardiac disease
  • Children with clinically significant chronic respiratory disease
  • Immunocompromised children
  • Children with a gestational age at birth less than 34 weeks
  • Children who received immunoprophylaxis therapy (i.e RSV immune globulin therapy)
  • Children who received corticosteroid in any form in the preceding 2 weeks before presentation
  • Children who received bronchodilators within 24 hours before presentation
  • Children with critical illness at presentation requiring immediate admission to intensive care unit

研究组 & 干预措施

NaCl 3% inhalations + standard therapy

Active Comparator

In this group, patients receive NaCl 3% inhalations ( 4ml QID) together with standard therapy.

Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed.

干预措施: NaCl 3% (Drug)

NaCl 3% inhalations + standard therapy

Active Comparator

In this group, patients receive NaCl 3% inhalations ( 4ml QID) together with standard therapy.

Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed.

干预措施: Standard therapy (Other)

Standard therapy

Placebo Comparator

Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed

干预措施: Standard therapy (Other)

结局指标

主要结局

length of hospital stay

时间窗: 2 years

The length of stay is defined as the time between study entry and the time at which the child reach protocol-defined discharge criteria as measured by the physician in charge.

次要结局

  • transfer rate to ICU(2 years)
  • adverse events(2 years)
  • Patients' ability to feed(2 years)
  • Wang clinical severity score evolution(2 years)
  • readmission rate in the next 7 days following discharge(2 years)

研究者

发起方
Raphaelle Jaquet-Pilloud
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Raphaelle Jaquet-Pilloud

Jean-Yves Pauchard, MD

Hôpital de L'Enfance

研究点 (1)

Loading locations...

相似试验